多潘立酮治疗继发进展型多发性硬化:Simon两阶段2期无效性试验
该开放标签、单中心、单臂2期无效性试验采用Simon两阶段设计,纳入81例继发进展型多发性硬化患者,每日接受多潘立酮10mg四次治疗1年。62例可分析患者中22例(35%)出现残疾显著恶化,接近预期40%且高于预设无效性阈值,未能拒绝无效性假设。多潘立酮耐受性尚可,但84%发生不良事件、15%发生严重不良事件。
要点
- 多潘立酮未能拒绝在继发进展型多发性硬化中减少残疾进展的无效性假设。
- 62例可分析患者中22例(35%)12个月时计时25英尺步行恶化≥20%。
- 研究期间催乳素水平较高的患者残疾进展风险显著较低。
核心结论
- 多潘立酮治疗未能拒绝在继发进展型多发性硬化中减少残疾进展的无效性。
- Simon两阶段试验模型可能是进展型多发性硬化2期研究的有用模型。
研究设计与样本
- 开放标签、Simon两阶段、单中心、2期、单臂无效性试验,在卡尔加里多发性硬化诊所进行。
- 纳入标准:年龄18至60岁、继发进展型多发性硬化、筛查时扩展残疾状态量表评分4.0至6.5、筛查时计时25英尺步行≥9秒。
- 患者接受多潘立酮10mg每日四次治疗1年,主要结局为12个月时计时25英尺步行较基线恶化≥20%。
- 筛查110例患者,81例接受治疗,64例完成随访,其中62例纳入分析。
主要发现
- 62例可分析患者中22例(35%)出现残疾显著恶化,接近预期比例40%且高于预设无效性阈值。
- 研究期间催乳素水平较高的患者残疾进展风险显著较低。
- 多潘立酮治疗耐受性尚可,但84%患者发生不良事件,15%发生严重不良事件。
临床怎么用
- 多潘立酮不应用于继发进展型多发性硬化的残疾进展治疗。
- 催乳素水平与残疾进展风险的关联值得进一步研究。
局限性
- 开放标签、单臂设计,无安慰剂对照。
- 单中心研究,样本量有限,62例纳入分析。
- 64例完成随访,存在失访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess whether treatment with the generic drug domperidone can reduce the progression of disability in secondary progressive multiple sclerosis (SPMS), we conducted a phase 2 futility trial following the Simon 2-stage design. METHODS: We enrolled patients in an open-label, Simon 2-stage, single-center, phase 2, single-arm futility trial at the Calgary Multiple Sclerosis Clinic if they met the following criteria: age of 18 to 60 years, SPMS, screening Expanded Disability Status Scale score of 4.0 to 6.5, and screening timed 25-ft walk (T25FW) of ≥9 seconds. Patients received domperidone 10 mg 4 times daily for 1 year. The primary outcome was worsening of disability, defined as worsening of the T25FW performance by ≥20% at 12 months compared to baseline. This trial is registered with ClinicalTrials.gov (NCT02308137). RESULTS: Between February 13, 2015, and January 3, 2020, 110 patients were screened, 81 received treatment, and 64 completed follow-up, of whom 62 were analyzed. The study did not meet its primary endpoint: 22 of 62 (35%) patients experienced significant worsening of disability, which is close to the expected proportion of 40% and above the predefined futility threshold. Patients with higher prolactin levels during the study had a significantly lower risk of disability progression, which may warrant further investigation. Domperidone treatment was reasonably well tolerated, but adverse events occurred in 84% and serious adverse events in 15% of patients. CONCLUSIONS: Domperidone treatment could not reject futility in reducing disability progression in SPMS. The Simon 2-stage trial model may be a useful model for phase 2 studies in progressive MS. TRIAL REGISTRATION INFORMATION: ClinicalTrials.gov Identifier: NCT02308137. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that in individuals with SPMS participating in a futility trial, domperidone treatment could not reject futility in reducing disability progression at 12 months.
引用
- Koch MW, Sage K, Kaur S, et al. Repurposing Domperidone in Secondary Progressive Multiple Sclerosis: A Simon 2-Stage Phase 2 Futility Trial. Neurology. 2021. PMID: 34038379. doi:10.1212/WNL.0000000000011863
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。